");vwo_$('head').append(_vwo_sel);return vwo_$('head')[0] && vwo_$('head')[0].lastChild;})("HEAD")}}, R_940895_48_1_2_0:{ fn:function(log,nonce=''){return (function(x) {
if(!vwo_$.fn.vwoRevertHtml){
return;
};
var ctx=vwo_$(x),el;
/*vwo_debug log("Revert","content",""); vwo_debug*/;
el=vwo_$('[vwo-element-id="1742919897117"]');
el.revertContentOp().remove();})("HEAD")}}, C_940895_48_1_2_1:{ fn:function(log,nonce=''){return (function(x) {var el,ctx=vwo_$(x);
/*vwo_debug log("editElement",".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)"); vwo_debug*/(el=vwo_$(".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)")).html("Hello! David Brancaccio here. Do you want instant access to the free online course - “Economics 101” - to understand basic economic concepts?");})(".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)")}}, R_940895_48_1_2_1:{ fn:function(log,nonce=''){return (function(x) {
if(!vwo_$.fn.vwoRevertHtml){
return;
};
var el,ctx=vwo_$(x);
/*vwo_debug log("Revert","editElement",".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)"); vwo_debug*/(el=vwo_$(".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)")).vwoRevertHtml();})(".stylingblock-content-margin-cell > table:nth-of-type(1) > tbody:nth-of-type(1) > tr:nth-of-type(1) > td:nth-of-type(1) > div:nth-of-type(1) > div:nth-of-type(1) > h2:nth-of-type(1) > span:nth-of-type(1)")}}, C_940895_48_1_2_2:{ fn:function(log,nonce=''){return (function(x) {var el,ctx=vwo_$(x);
/*vwo_debug log("content","[vwo-element-id='1742482566780']"); vwo_debug*/(el=vwo_$("[vwo-element-id='1742482566780']")).replaceWith2("You'll gain real-world insights into how economics impacts your daily life with this easy-to-follow online course. This crash course is based on the acclaimed textbook Economy, Society, and Public Policy by CORE Econ, tailored to help you grasp key concepts without feeling overwhelmed.
Whether you're new to economics or just want to deepen your understanding, this course covers the basics and connects them to today’s pressing issues—from inequality to public policy decisions.
Each week, you'll receive a reading guide that distills core principles, offers actionable takeaways, and explains how they affect the current world. While the full ebook enriches the experience, the guides alone provide a comprehensive understanding of fundamental economic ideas.
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Drug companies challenge Minnesota prescription discount law in federal court
"This is just par for the course for the big pharmaceutical companies that are always trying to jack up their prices at the expense of people’s health," Attorney General Keith Ellison said.
Several drug companies filed lawsuits in federal court this week challenging a Minnesota law governing the price of medication, saying its inclusion in a bill regulating cannabis and the authority of the state to regulate discounts are misplaced.
Drug manufacturers AbbVie, AstraZeneca, Allergan, Durata Therapeutics, Pharmacyclics and Aptalis Pharma filed complaints in the U.S. District Court for the District of Minnesota.
They take issue with a provision of the expansive law that requires them to “restrict, prohibit or interfere” with the delivery of a drug available through a federal program that helps send discounted medicines to hospitals that treat low-income and uninsured patients.
The companies said Minnesota doesn’t have the authority to enforce what’s known as the 340B program or to require drug manufacturers to turn over their property without due process.
Turn Up Your Support
MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all.
“It effectively gives covered entities unfettered authority to take manufacturers’ property for the benefit of private parties of their choice,” attorneys representing AbbVie wrote in their complaint.
They argued that the policy also runs afoul of state and federal laws requiring that legislation only address a single subject. They asked the court to deem the law unconstitutional and block it from taking effect.
Spokespeople for AbbVie and AstraZeneca didn’t immediately respond to requests for comment on the lawsuit Wednesday.
Sen. Alice Mann, DFL-Edina, is an emergency room physician and sponsored the proposal dealing with the 340B program that got wrapped up in the larger bill. She said the policy was needed to ensure that drug companies continued to supply affordable medicines after some had limited pharmacies and hospitals that were eligible in recent years.
“We simply made sure that we were following federal law, as it was intended to be followed,” Mann said. “Any time we cut into [drug manufacturers’] billion-dollar profit margins, they come after the law, and they sue the state, they sue the federal government. This is not new, this is very much the pharmaceutical playbook.”
Mann said that other states had taken similar steps to ensure that drug manufacturers complied with the federal law and overcame legal challenges from companies.
Attorney General Keith Ellison, who is set to defend the law against the challenges, told MPR News that he wasn’t surprised to see the drug makers challenge the policy.
“The fact is it’s not unconstitutional,” Ellison said. “It’s an important and very good program. And yet this is just par for the course for the big pharmaceutical companies that are always trying to jack up their prices at the expense of people’s health.”
When it comes to staying informed in Minnesota, our newsletters overdeliver. Sign-up now for headlines, breaking news, hometown stories, weather and much more. Delivered weekday mornings.